公开(公告)号：US11696893B2

公开(公告)日：2023-07-11

申请号：US16629096

申请日：2018-07-09

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Hiroyuki Fujii ,  Akira Suzuki

IPC: A61K9/14 ,  A61K9/00 ,  A61K9/20 ,  A61K31/4439 ,  A61K47/12

CPC classification number: A61K9/14 ,  A61K9/0056 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K31/4439 ,  A61K47/12

Abstract: The present invention aims to provide a preparation expected to improve the bitter taste of an organic acid salt of vonoprazan and permit rapid dissolution of the organic acid salt of vonoprazan after administration.
The present invention provides a preparation containing fine granules or granules containing (1) a core granule containing an organic acid salt of vonoprazan, (2) an intermediate layer containing the same organic acid as the organic acid forming the salt of vonoprazan in (1), or a salt thereof, and (3) a coating layer containing a water-insoluble polymer.

公开(公告)号：US20230211017A1

公开(公告)日：2023-07-06

申请号：US18145784

申请日：2022-12-22

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Hanspeter Rottensteiner ,  Friedrich Scheiflinger

IPC: A61K48/00 ,  A61P7/04

CPC classification number: A61K48/0066 ,  A61K48/0058 ,  A61P7/04

Abstract: The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor VIII variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia A.

公开(公告)号：US20230203186A1

公开(公告)日：2023-06-29

申请号：US17810377

申请日：2022-07-01

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Kathleen Ann Elias ,  Gregory Landes ,  Shweta Singh ,  Wouter Korver ,  Andrew Walling Drake ,  Mary Haak-Frendscho ,  Vinay Bhaskar ,  Erin Willert

IPC: C07K16/28

CPC classification number: C07K16/2896 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92

Abstract: Provided in this disclosure are anti-CD38 binding domains, a composition comprising the anti-CD38 binding domains, nucleic acids encoding the anti-CD38 binding domains, and a method of using the anti-CD38 binding domains or the composition for treating multiple myeloma.

公开(公告)号：US20230201227A1

公开(公告)日：2023-06-29

申请号：US18184918

申请日：2023-03-16

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Richard Labotka ,  Andrew Fergus

IPC: A61K31/69 ,  C07K16/28 ,  A61P35/00 ,  A61K45/06 ,  A61K39/395

CPC classification number: A61K31/69 ,  A61K39/3955 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2896 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2317/73

Abstract: The present disclosure relates to methods for treating cancer, or preventing cancer recurrence or progression, comprising administering a patient an anti-CD38 antibody and a proteasome inhibitor.

公开(公告)号：US11684632B2

公开(公告)日：2023-06-27

申请号：US16983310

申请日：2020-08-03

Applicant: Takeda Pharmaceutical Company Limited

Inventor： John D. Peabody, III

IPC: A61K31/7056 ,  G09B19/00 ,  A61K45/06 ,  G01N33/94

CPC classification number: A61K31/7056 ,  A61K45/06 ,  G01N33/94 ,  G09B19/00 ,  G01N2430/00 ,  G01N2800/52

Abstract: The invention relates to novel compositions and methods of using maribavir which enhance its effectiveness in medical therapy, as well as to maribavir isomers and methods of use thereof for counteracting the potentially adverse effects of maribavir isomerization in vivo in the event it occurs.

公开(公告)号：US20230192685A1

公开(公告)日：2023-06-22

申请号：US17927584

申请日：2021-05-26

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Hitoaki NISHIKAWA ,  Naohiro TAYA ,  Hiroshi BANNO ,  Masatoshi YAMADA ,  Kazuki AZUMA ,  Ayaka SUZUKI

IPC: C07D471/04

CPC classification number: C07D471/04

Abstract: A method for producing a compound represented by the formula (X):




or a salt thereof and has a MALT1 inhibitory action, the said method containing a step for producing a compound a compound represented by the formula (B-2):




or a salt thereof and being characterized by comprising crystallizing a salt of a compound represented by the formula (B-1)




and an optically active organic acid.

(In the formulae, each symbol is as defined in the specification.)

公开(公告)号：USD989279S1

公开(公告)日：2023-06-13

申请号：US29759683

申请日：2020-11-24

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Designer： Shekhar Nimkar ,  Adam C. Fox ,  Jessica Diane Young ,  Beverly Anne Piatt ,  James Alan Prescott ,  William G. Atterbury ,  Andrew V. Sweeney

Abstract: FIG. 1 is an upper perspective view of a first embodiment of our new design for a fluid delivery device.
FIG. 2 is a lower perspective view thereof.
FIG. 3 is a back elevation view thereof.
FIG. 4 is a front elevation view thereof.
FIG. 5 is a left elevation view thereof.
FIG. 6 is a right elevation view thereof.
FIG. 7 is a top plan view thereof.
FIG. 8 is a bottom plan view thereof.
FIG. 9 is an upper perspective view of a second embodiment of our new design for a fluid delivery device.
FIG. 10 is a lower perspective view thereof.
FIG. 11 is a back elevation view thereof.
FIG. 12 is a front elevation view thereof.
FIG. 13 is a left elevation view thereof.
FIG. 14 is a right elevation view thereof.
FIG. 15 is a top plan view thereof; and,
FIG. 16 is a bottom plan view thereof.
The broken lines shown in the figures depict portions of the fluid delivery device that form no part of the claimed design. The shade lines shown represent surface shading and not surface ornamentation or material type.

公开(公告)号：US20230143604A1

公开(公告)日：2023-05-11

申请号：US17914013

申请日：2021-03-25

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Antoine Charles Olivier HENNINOT ,  Derek Cecil COLE ,  Nicholas SCORAH

IPC: A61K38/26 ,  C07K14/605

CPC classification number: A61K38/26 ,  C07K14/605

Abstract: The present disclosure provides GIP receptor agonist peptide compounds suitable for once per week dosing (QW), said peptide compounds having an activating action on GIP receptors and use of the GIP receptor agonist peptide as a medicament for the treatment and/or prevention of emesis, or a symptom or condition associated with emesis. Specifically, a GIP receptor agonist peptide containing a sequence represented by any of the formulas (I)-(V) or a salt thereof, and a medicament comprising the same are provided.

公开(公告)号：US20230143477A1

公开(公告)日：2023-05-11

申请号：US17995198

申请日：2021-04-02

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Ayesha Arzumand ,  Chris Tarapata ,  Marc Bellisario ,  Christel Hartshorn ,  Matthew J. Gunn ,  Chase Fetzer

IPC: A61M39/02 ,  A61M39/04

CPC classification number: A61M39/0208 ,  A61M39/04

Abstract: A subcutaneous port assembly includes a base, a connector, a stem, a sealing element, and a locking member. The connector extends from a first end attached to the base to a distal end and includes an inner surface defining a socket having an inside diameter. The stem extends from the base and into the socket. The stem includes an outer surface having an outside diameter that is less than the inside diameter of the socket. The sealing element is disposed within the socket between the stem and the inner surface of the socket. The locking member has a plunger received within the socket from the distal end and having a terminal end facing the sealing element. The plunger is axially movable between a first position and a second position to selectively compress the sealing element within the socket.

公开(公告)号：US20230117565A1

公开(公告)日：2023-04-20

申请号：US17838769

申请日：2022-06-13

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Stephen R. Comeau ,  Andrew Nixon ,  Niksa Kastrapeli ,  Jon A. Kenniston ,  Gregory P. Conley ,  Shauna Mason ,  Allison P. Lindberg ,  Kristopher Kopacz ,  Burt Adelman

IPC: C07K16/40 ,  C07K16/36 ,  A61P7/02 ,  A61K39/395 ,  C12N9/64

Abstract: Described herein are bispecific antibodies that bind to plasma kallikrein (pKal) and Factor XII and methods of producing and using such bi-specific antibodies for treating diseases or disorders associated with the contact system, e.g., hereditary angioedema or thrombosis.